Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$7.57M | -$19.8M | -$71.2M | -$76.2M | -$134M | -$167M | -$224M | -$260M | -$273M | -$232M |
| Net income | -$7.57M | -$19.6M | -$74.5M | -$77.3M | -$140M | -$169M | -$222M | -$246M | -$259M | -$223M |
| EPS (diluted) | -$1.11 | -$2.88 | -$1.89 | -$1.58 | -$2.52 | -$2.67 | -$3.26 | -$2.92 | -$2.73 | -$2.01 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.50M | -$16.0M | -$53.8M | -$64.7M | -$74.6M | -$121M | -$178M | -$195M | -$210M | -$190M |
| Capital expenditures | $335K | $760K | $1.45M | $23.3M | $20.6M | $7.62M | $8.36M | $16.4M | $5.86M | $440K |
| Free cash flow | -$5.84M | -$16.7M | -$55.2M | -$87.9M | -$95.2M | -$129M | -$187M | -$211M | -$216M | -$190M |
| Share buybacks | $0.00 | $0.00 | $0.00 | $0.00 | $72.0K | $0.00 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $29.8M | $18.1M | $111M | $185M | $297M | $233M | $141M | $55.9M | $164M | $77.6M |
| Total assets | $130M | $20.1M | $251M | $372M | $591M | $497M | $552M | $566M | $528M | $330M |
| Total liabilities | $56.5M | $4.63M | $57.3M | $64.8M | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Shareholders' equity | $8.37M | $15.5M | $194M | $307M | $504M | $455M | $490M | $493M | $463M | $277M |
| Retained earnings | -$239M | -$31.4M | -$106M | -$183M | -$323M | -$492M | -$714M | -$959M | -$1.22B | -$1.44B |
| Shares (wtd avg diluted) | 6.75M | 6.80M | 45.1M | 49.0M | 55.4M | 63.2M | 68.1M | 84.0M | 94.8M | 111M |
Every figure is extracted from ROCKET PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.